04:38 PM EDT, 05/06/2024 (MT Newswires) -- Vertex Pharmaceuticals ( VRTX ) posted Q1 non-GAAP earnings late Monday of $4.76 per diluted share, up from $3.05 a year ago.

Analysts polled by Capital IQ expected $4.06.

Product revenue for the quarter ended March 31 was $2.69 billion, up from $2.38 billion a year earlier.

Analysts surveyed by Capital IQ expected revenue of $2.58 billion.

The company reiterated its full year 2024 product revenue guidance of between $10.55 billion and $10.75 billion.

Analysts polled by Capital IQ expect revenue of $10.72 billion.

Price: 406.00, Change: +3.50, Percent Change: +0.87